Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets

Tyrosine kinase inhibitors (TKI) such as the BCR-ABL inhibitor dasatinib and nilotinib are highly effective therapies for chronic myeloid leukemia (CML). However, several lines of evidence suggest that dasatinib can induce bleeding which may be due to impaired collagen-induced platelet adhesion, agg...

Descripción completa

Detalles Bibliográficos
Autores principales: Beke Debreceni, Ildikó, Mezei, Gabriella, Batár, Péter, Illés, Árpád, Kappelmayer, János
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862041/
https://www.ncbi.nlm.nih.gov/pubmed/31683623
http://dx.doi.org/10.3390/ijms20215430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862041/
https://www.ncbi.nlm.nih.gov/pubmed/31683623
http://dx.doi.org/10.3390/ijms20215430

Ejemplares similares